Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

JasonCO Feb. 17 at 8:17 PM

$PRME $3.17 was a add

1 · Reply

Elamenape2 Feb. 17 at 5:59 PM

$PRME Wishful thinking , but it would be wonderful if the result of the arbitration with BEAM ends in just a straight up merger. David Liu’s brilliance should be under one roof.

0 · Reply

PorkchopSquats Feb. 17 at 4:15 PM

$PRME Keeps bouncing where it should. Still directionless. Chop chop.

0 · Reply

Lawneverchase Feb. 17 at 3:15 PM

$PRME Buyer at 2.97

0 · Reply

Elamenape2 Feb. 17 at 3:13 PM

$PRME

0 · Reply

arg195 Feb. 17 at 3:02 PM

$PRME down 20% in the past month, wen low 2s?

0 · Reply

Mcnulty_jimmy Feb. 17 at 2:54 PM

$PRME Daily Deion

0 · Reply

someguytrades Feb. 17 at 2:53 PM

$PRME 3.47 to 3.21 on zero volume. Just pure algo selling without a single buyer. No one wants it

0 · Reply

someguytrades Feb. 17 at 2:45 PM

$PRME just send it to zero, what are we waiting for

0 · Reply

3DBuilds Feb. 17 at 12:05 PM

$NTLA $CRBU $EDIT $PRME $JNJ Jennifer 💯 💰 🌎

0 · Reply

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:00 AM EST - 5 weeks ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 1:29 PM EST - 6 weeks ago

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Dec 7, 2025, 8:05 AM EST - 2 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Nov 25, 2025, 8:00 AM EST - 3 months ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 2:51 PM EST - 3 months ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 11, 2025, 8:00 AM EST - 3 months ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 7, 2025, 10:21 AM EST - 3 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 3 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 8:01 AM EST - 3 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Oct 30, 2025, 4:01 PM EDT - 3 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Sep 8, 2025, 5:38 PM EDT - 5 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 5 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 1, 2025, 4:01 PM EDT - 7 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 30, 2025, 9:33 PM EDT - 7 months ago

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 4:01 PM EDT - 7 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 16, 2025, 8:10 AM EDT - 7 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 7:00 AM EDT - 7 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 7, 2025, 4:45 PM EDT - 8 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

May 19, 2025, 8:31 AM EDT - 9 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 9 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 10 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 1 year ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Jan 28, 2024, 8:11 AM EST - 2 years ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 25, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 2 years ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 2, 2024, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 2:45 PM EST - 2 years ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

JasonCO Feb. 17 at 8:17 PM

$PRME $3.17 was a add

1 · Reply

Elamenape2 Feb. 17 at 5:59 PM

$PRME Wishful thinking , but it would be wonderful if the result of the arbitration with BEAM ends in just a straight up merger. David Liu’s brilliance should be under one roof.

0 · Reply

PorkchopSquats Feb. 17 at 4:15 PM

$PRME Keeps bouncing where it should. Still directionless. Chop chop.

0 · Reply

Lawneverchase Feb. 17 at 3:15 PM

$PRME Buyer at 2.97

0 · Reply

Elamenape2 Feb. 17 at 3:13 PM

$PRME

0 · Reply

arg195 Feb. 17 at 3:02 PM

$PRME down 20% in the past month, wen low 2s?

0 · Reply

Mcnulty_jimmy Feb. 17 at 2:54 PM

$PRME Daily Deion

0 · Reply

someguytrades Feb. 17 at 2:53 PM

$PRME 3.47 to 3.21 on zero volume. Just pure algo selling without a single buyer. No one wants it

0 · Reply

someguytrades Feb. 17 at 2:45 PM

$PRME just send it to zero, what are we waiting for

0 · Reply

3DBuilds Feb. 17 at 12:05 PM

$NTLA $CRBU $EDIT $PRME $JNJ Jennifer 💯 💰 🌎

0 · Reply

Elamenape2 Feb. 15 at 8:37 PM

$PRME

0 · Reply

someguytrades Feb. 13 at 10:36 PM

$NTLA $30, $BEAM $150 $CRSP $100 $PRME $1.50

2 · Reply

arg195 Feb. 13 at 8:53 PM

$PRME down 5% in the last 6 months. SPY up 5% in the same timeframe. You were sold hopium

2 · Reply

WillyBoyQc Feb. 13 at 8:51 PM

$PRME Keep it simple, 9 daily SMA is clearly acting as resistance now + trading below the 200 daily SMA. Will move like shit as long as its below both. Only positive, its holding the range were it generally bounced the last 6 months. Still holding my 3.80 starter, will dump if range breaks / whole market shits itself.

1 · Reply

someguytrades Feb. 13 at 8:36 PM

$PRME twitter crowd giving up, should have better price action soon finally.

0 · Reply

someguytrades Feb. 13 at 8:16 PM

$PRME just close red at this point

0 · Reply

someguytrades Feb. 13 at 8:15 PM

$PRME lololol it actually gave everything back, we are so cooked

0 · Reply

Elamenape2 Feb. 13 at 6:54 PM

$PRME Time to enjoy the weekend!

0 · Reply

arg195 Feb. 13 at 3:46 PM

$PRME don't chase here, wait because the markets will drop which will ruin lives according to @sogenerous

0 · Reply

JasonCO Feb. 13 at 3:38 PM

$PRME send it mother f’ers

0 · Reply

StockMarketGuru Feb. 13 at 3:25 PM

$PRME CRSP up 8%!

0 · Reply

someguytrades Feb. 13 at 3:11 PM

$PRME hardly catching a bid while the whole gene editing sector rips, F

0 · Reply

Market Cap	595.69M
Revenue (ttm)	2.98M
Net Income (ttm)	-195.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,573.15%
Debt to Equity Ratio	0.00

Volume	1,159,829
Avg Vol	3,375,622
Day's Range	N/A - N/A
Shares Out	180.51M
Stochastic %K	12%
Beta	2.70
Analysts	Strong Sell
Price Target	$6.46